Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 8/20 | 0.38 |
| ▸ | TYK2 | P29597 | 6/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29546485 | 0.84 | TYK2 (0.41) | ALOX5TYK2JAK1JAK2 | |
| SCHEMBL31543517 | 0.80 | ALOX5 (0.38) | ALOX5TYK2JAK1JAK2 | |
| SCHEMBL21330053 | 0.80 | ALOX5 (0.36) | ALOX5TYK2JAK1JAK2 | |
| SCHEMBL21330071 | 0.80 | TYK2 (0.36) | ALOX5TYK2JAK1JAK2 | |
| SCHEMBL31691849 | 0.78 | ALOX5 (0.43) | ALOX5TYK2JAK1OPRM1CYP2D6 | |
| SCHEMBL21330103 | 0.78 | ALOX5 (0.43) | ALOX5TYK2JAK1OPRM1CYP2D6 | |
| SCHEMBL31691896 | 0.78 | TYK2 (0.45) | ALOX5TYK2JAK1 | |
| SCHEMBL21329875 | 0.77 | ALOX5 (0.34) | ALOX5TYK2JAK1JAK2 | |
| SCHEMBL31161395 | 0.76 | TYK2 (0.36) | ALOX5TYK2JAK1JAK2 | |
| SCHEMBL31692046 | 0.76 | ALOX5 (0.40) | ALOX5TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304577-A1 | TYK2 INHIBITORS | BIOGEN MA INC. | 2025-10-02 | — | — | US | disclosed |
| EP-4522612-A1 | TYK2 INHIBITORS | Biogen MA Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-119654322-A | TYK2 inhibitors | 渤健马萨诸塞州股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| WO-2023220046-A1 | TYK2 INHIBITORS | BIOGEN MA INC. (US) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304577-A1 | TYK2 INHIBITORS | TYK2, JAK2, JAK1 | ALOX5 4280/4885TYK2 1/4885JAK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.